Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gumetinib + osimertinib versus platinum-doublet chemotherapy in EGFR-TKI-resistant MET-altered NSCLC
CTR20250466Phase 3Active
- Sponsor
- Haihe
- Start
- Apr 2025
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of gumetinib, osimertinib, pemetrexed, carboplatin, cisplatin in non-small cell lung cancer (NSCLC), sponsored by Haihe. Started Apr 2025; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20250466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250466.